Chambers S K, Chambers J T, Kohorn E I, Schwartz P E
Gynecol Oncol. 1987 Jun;27(2):233-40. doi: 10.1016/0090-8258(87)90298-8.
Twenty-two patients with advanced epithelial ovarian cancer were treated with etoposide and cis-platinum. Each had failed one to three regimens of combination chemotherapy including cis-platinum-based combinations. Prior total cis-platinum doses ranged from 50 to 1600 mg/m2 with a median of 440 mg/m2. One of 18 evaluable patients had a complete response lasting 8 months, 1 had a partial response lasting 3 months, 8 had stable disease for a mean of 5.6 months, and 8 had progressive disease. The 4 unevaluable patients had undetectable clinical disease for a mean of 6.7 months. Bone marrow suppression was seen in 4 of 22 patients; two of whom had serious sequelae. The poor objective response rate (9.1%) seen with this combination in patients heavily pretreated with cis-platinum is similar to that seen for single agent etoposide in patients pretreated with alkylating agents. The difficulty of obtaining a good objective response in the face of prior cis-platinum-based combination chemotherapy failure is again verified.
22例晚期上皮性卵巢癌患者接受了依托泊苷和顺铂治疗。每位患者之前均接受过1至3种联合化疗方案，包括以顺铂为基础的联合方案，但均治疗失败。之前顺铂的总剂量范围为50至1600mg/m²，中位数为440mg/m²。18例可评估患者中，1例完全缓解持续8个月，1例部分缓解持续3个月，8例病情稳定平均持续5.6个月，8例病情进展。4例不可评估患者临床疾病未检测到平均持续6.7个月。22例患者中有4例出现骨髓抑制；其中2例有严重后遗症。在接受过大量顺铂预处理的患者中，该联合方案的客观缓解率较低（9.1%），这与在接受过烷化剂预处理的患者中使用单药依托泊苷的情况相似。面对之前基于顺铂的联合化疗失败，难以获得良好客观缓解这一情况再次得到证实。
